Real world retrospective analysis of luliconazole 1% and salicylic acid 3% as fixed dose combination in the management of hyperkeratotic dermatophytosis in India
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20205013Keywords:
Hyperkeratotic dermatophytosis, Luliconazole, Salicylic acid, India, RetrospectiveAbstract
Background: In recent times, there is increase in prevalence of hyperkeratotic dermatophytosis in India. These hyperkeratotic lesions usually impede the absorption of topical anti-mycotic agent making infection recalcitrant to topical anti-fungal therapy alone. Hence, many times topical keratolytic are used in combination with topical anti-fungal agents which augment the shedding of scales.
Methods: To seek for short period therapy in hyperkeratotic dermatophytosis, we conducted multicentre, retrospective data analysis at 61 dermatology clinics to study effectiveness and safety of Luliconazole 1% and Salicylic acid 3% fixed dose combination (FDC) cream for 2 weeks.
Results: A data of 191 patients’ were included in this analysis. All patients have received some of the topicals and switched to FDC. Total symptom score of 7.19±1.91 improved to 3.15±1.12 in just 2 weeks (p<0.05). The clinical improvement rate (percentage of ‘marked improvement’ plus ‘moderate improvement’) was 78% after 2 weeks of treatment. Moreover, 5 patients (2.61%) achieved complete clearance. This FDC was found to be safe in 51.83% (n=99) of the patients whereas 37.7% of the patients (n=72) reported it as almost safe. Minor problems with the safety was found in 9.42% of the patients (n=18). Two patients (1.04%) reported it as not safe and thus shifted to another drug. Irritation and burning were reported as most common adverse events (AE).
Conclusions: The short combination therapy with luliconazole and salicylic acid as FDC has been found to be effective and safe. It should be a valuable option for hyperkeratotic dermatophytosis for early achievement of clinical cure and better patient compliance.
References
Leyden JL. Tinea pedis pathophysiology and treatment. J Am Acad Dermatol. 1994;31(2):S31-S33.
Richardson M, Elewski B. Superficial Fungal Infections. Oxford: Health Press Limited. 2000.
Rupke SJ. Fungal skin disorders. Prim Care. 2000;27:407-21.
Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, et al. Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18(1):6.
Sardana K, Khurana A. Overview of causes and treatment of recalcitrant dermatophytoses. In: Sardana K, editor. IADVL Manual on Management of Dermatophytoses. 1st ed. India: CBS Publishers and Distributors Pvt., Ltd. 2018;80‑104.
Saoji V, Madke B. Efficacy of salicylic acid peel in dermatophytosis. Indian J Dermatol Venereol Leprol. 2019;10.4103.
Tanuma H, Tanuma M, Abe M, Kume H. Usefulness of lanoconazole (Astat) cream in the treatment of hyperkeratotic type tinea pedis. Comparative study of monotherapy and combination therapy with 10% urea ointment (Pastaron). Mycoses. 2001;44(5):181-90.
Tanuma H, Doi M, Sato N, Nishiyama S, Abe M, Kume H et al. Bifonazole (Mycospor cream) in the treatment of moccasin-type tinea pedis. Comparison between combination therapy of bifonazole cream + 10% urea ointment (Urepearl) and occlusive dressing therapy with the same agents. Mycoses. 2000;43(3-4):129-37.
Elewski BE, Haley HR, Robbins CM. The use of 40% urea cream in the treatment of moccasin tinea pedis. Cutis. 2004;73(5):355-7.
Taylor JR, Halprin KM. Percutaneous absorption of salicylic acid. Arch Dermatol. 1975;111:740‑3.
Bari AU, Iqbal Z, Rahman SB. Tolerance and safety of superficial chemical peeling with salicylic acid in various facial dermatoses. Indian J Dermatol Venereol Leprol. 2005;71:87‑90.
Das S, De A, Saha R, Sharma N, Khemka M, Singh S, et al. The Current Indian Epidemic of Dermatophytosis: A Study on Causative Agents and Sensitivity Patterns. Indian J Dermatol. 2020;65(2):118-22.
